Hydroxychloroquine

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Rheumatoid Arthritis, Systemic Lupus Erythematosus

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

Also approved (2)
US
  • Malaria PLAQUENIL is indicated in adult and pediatric patients for the: • Treatment of uncomplicated malaria due to Plasmodium falciparum, Plasmodium malariae, Plasmodium vivax, and Plasmodium ovale. • Prophylaxis of malaria in geographic areas where chloroquine resistance is not reported.
  • Chronic Discoid Lupus Erythematosus PLAQUENIL is indicated for the treatment of chronic discoid lupus erythematosus in adults.Outside this platform's coverage
Product first approved 1955FDA label

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

This page stands for the molecule. Studies that name only the molecule, and no branded product, are listed here and are marked as studies of the molecule. A study of a branded product is on that product's page.

Phase 3 (93)
Rheumatoid Arthritis
NCT03414502 · University of Nebraska
2007-12-10 – 2029-03 · Rheumatoid Arthritis
What this study did
NCT02930343 · Jawaharlal Institute of Postgraduate Medical Education & Research
2016-09 – 2018-08 · Rheumatoid Arthritis
What this study did
NCT02057250 · Sanofi
2014-03 – 2016-03 · RA
What this study did
NCT01132118 · Brigham and Women's Hospital
2010-06 – 2012-06 · Rheumatoid Arthritis, Insulin Resistance
What this study did
NCT00579878 · University of Nebraska
2001-03-27 – 2010-03-11 · Rheumatoid Arthritis
What this study did
Systemic Lupus Erythematosus
NCT05799378 · NYU Langone Health
2024-06-27 – 2029-06-30 · Systemic Lupus Erythematosus
What this study did
Other / comorbidity
NCT04381936 · University of Oxford
2020-03-19 – 2038-09-30 · Pneumonia
What this study did
NCT07830108 · Starship Child Health, Te Toka Tumai Auckland
2026-12 – 2036-12 · Rheumatic Fever, Rheumatic Heart Disease in Children, Acute Rheumatic Fever, Rheumatic Heart Disease
What this study did
NCT07265297 · National Taiwan University Hospital
2025-08-12 – 2030-12-31 · Steatohepatitis, Nonalcoholic
What this study did
NCT07061717 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2025-07-01 – 2029-07-01 · Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer
What this study did
NCT02735707 · UMC Utrecht
2016-04-11 – 2029-02 · Respiratory Tract Diseases, Influenza (Pandemic), Influenza, Community Acquired Pneumonia, Community Acquired Pneumonia (CAP), Community Acquired Pneumonia, Severe, COVID-19, Respiratory Tract Infection Acute, Respiratory Tract Infections (RTI), SARS CoV 2 Infection
What this study did
NCT05287321 · Samsung Medical Center
2022-05-31 – 2028-12-31 · Preeclampsia
What this study did
NCT03165136 · University Hospital, Brest
2017-12-04 – 2026-02-01 · Recurrent Miscarriage, First Trimester Abortion
What this study did
NCT05737680 · Hippocration General Hospital
2023-02 – 2024-12 · Pericarditis Idiopathic Recurrent
What this study did
NCT05247554 · Assistance Publique - Hôpitaux de Paris
2022-03-01 – 2024-03-01 · Pulmonary Sarcoidosis
What this study did
NCT04315948 · Institut National de la Santé Et de la Recherche Médicale, France
2020-03-22 – 2023-09-25 · Corona Virus Infection
What this study did
NCT04372082 · University Hospital, Lille
2020-05 – 2023-05 · Sars-CoV2
What this study did
NCT03305263 · Copenhagen University Hospital, Rigshospitalet
2018-01-25 – 2023-01 · Recurrent Pregnancy Loss
What this study did
NCT03540810 · University Hospital, Angers
2018-08-15 – 2022-10-15 · Primary Antiphospholipid Syndrome
What this study did
NCT04359953 · University Hospital, Strasbourg, France
2020-04-25 – 2022-06-01 · COVID-19 Infection
What this study did
NCT04328285 · Centre Hospitalier Universitaire de Saint Etienne
2020-04-14 – 2022-03-30 · COVID-19
What this study did
NCT04344444 · LCMC Health
2020-04-13 – 2022-01-05 · COVID-19
What this study did
NCT04334382 · Intermountain Health Care, Inc.
2020-04-02 – 2021-12-31 · COVID-19
What this study did
NCT04410562 · Barcelona Institute for Global Health
2020-05-13 – 2021-10-31 · Pregnancy Related, COVID, Covid-19
What this study did
NCT05026801 · Iterum Therapeutics, International Limited
2021-02-08 – 2021-08-26 · Respiratory Tract Infection Viral
What this study did
NCT04363203 · Salomeh Keyhani MD
2020-04-30 – 2021-08 · SARS-CoV-2, COVID-19
What this study did
NCT04334928 · Plan Nacional sobre el Sida (PNS)
2020-04-15 – 2021-07-11 · Coronavirus Infection
What this study did
NCT04360759 · University of Cape Town
2020-05-01 – 2021-06-30 · Covid-19, HIV
What this study did
NCT04858633 · Post Graduate Institute of Medical Education and Research, Chandigarh
2021-03-22 – 2021-06-30 · Covid19, COVID-19 Prevention
What this study did
NCT04372017 · Sanford Health
2020-05-14 – 2021-06-04 · COVID-19, SARS-CoV 2
What this study did
NCT04363450 · Louisiana State University Health Sciences Center in New Orleans
2020-04-27 – 2021-06-01 · COVID-19, Corona Virus Infection, Wuhan Coronavirus, Prophylaxis, Healthcare Worker, Sars-CoV2, Hydroxychloroquine
What this study did
NCT04364815 · University of the Philippines
2020-12 – 2021-05 · COVID-19
What this study did
NCT04397328 · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
2020-05-30 – 2021-04-30 · COVID-19
What this study did
NCT04365582 · Fondation Hôpital Saint-Joseph
2020-05-07 – 2021-04-19 · COVID
What this study did
NCT04365231 · Hospital St. Joseph, Marseille, France
2020-04-01 – 2021-04-01 · COVID19
What this study did
NCT04341727 · Washington University School of Medicine
2020-04-04 – 2021-04-01 · Coronavirus Infection
What this study did
NCT04352933 · Cambridge University Hospitals NHS Foundation Trust
2020-05-11 – 2021-04 · COVID-19
What this study did
NCT04318015 · National Institute of Respiratory Diseases, Mexico
2020-04-14 – 2021-03-31 · COVID-19, Severe Acute Respiratory Syndrome
What this study did
NCT04374942 · Megan Landes
2020-04-30 – 2021-03-31 · Pre-Exposure Prophylaxis, Coronavirus, SARS-CoV 2
What this study did
NCT04342221 · University Hospital Tuebingen
2020-03-29 – 2021-02-26 · COVID-19, Hydroxychloroquine Sulfate
What this study did
NCT04981379 · Health Institutes of Turkey
2020-11-16 – 2021-02-16 · Covid19
What this study did
NCT04403100 · Cardresearch
2020-06-03 – 2021-02-01 · COVID-19, Coronavirus Infection, Virus Disease, Acute Respiratory Infection, SARS-CoV Infection
What this study did
NCT04334148 · Adrian Hernandez
2020-04-22 – 2021-01-09 · COVID-19
What this study did
NCT04331834 · Barcelona Institute for Global Health
2020-04-03 – 2020-12-31 · COVID-19
What this study did
NCT04788355 · Universidade do Vale do Sapucai
2020-07-01 – 2020-12-23 · Complication
What this study did
NCT04341441 · Henry Ford Health System
2020-04-07 – 2020-12-15 · COVID-19, Coronavirus, Coronavirus Infections, SARS-CoV 2
What this study did
NCT04414241 · Universidad Peruana Cayetano Heredia
2020-06-25 – 2020-11-23 · SARS-CoV-2
What this study did
Phase 2/3 (23)
Other / comorbidity
NCT05961202 · Tongji Hospital
2021-11-01 – 2025-11-01 · Inflammatory Cardiomyopathy, Myocarditis
What this study did
NCT04389359 · Cambridge University Hospitals NHS Foundation Trust
2020-09 – 2025-08 · COVID-19
What this study did
NCT05084872 · University Hospital, Toulouse
2021-10 – 2024-01 · Mastocytosis
What this study did
NCT04385264 · Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland
2022-01 – 2022-12 · COVID-19
What this study did
NCT04351724 · Medical University of Vienna
2020-04-16 – 2022-03-31 · COVID-19
What this study did
NCT04437693 · Hamad Medical Corporation
2020-08-31 – 2021-12-31 · COVID 19
What this study did
NCT04964583 · Coordinación de Investigación en Salud, Mexico
2021-01-20 – 2021-08 · Covid19
What this study did
NCT04351516 · University Hospital Tuebingen
2020-04-21 – 2021-05-01 · SARS-CoV 2, COVID-19
What this study did
NCT04712279 · Corpometria Institute
2021-01-25 – 2021-04-20 · Covid19
What this study did
NCT04345861 · University Hospital, Montpellier
2020-04-11 – 2021-04-09 · Coronavirus Infection, Pneumonia, Viral
What this study did
NCT04400019 · University of Malaga
2020-09 – 2021-04-01 · Sars-CoV2, Coronavirus Infection, Prevention & Control, Nursing Home, Hydroxychloroquine
What this study did
NCT04318444 · Columbia University
2020-03-29 – 2021-03-31 · COVID-19, Corona Virus Infection
What this study did
NCT04597775 · Regional Center for Disease Control and Prevention, Jordan
2020-10-27 – 2021-01-31 · SARS-CoV Infection
What this study did
NCT04443725 · Cairo University
2020-07 – 2020-12 · COVID-19
What this study did
NCT04361318 · Tanta University
2020-05 – 2020-12 · COVID-19
What this study did
NCT04354428 · University of Washington
2020-04-16 – 2020-11-30 · COVID-19, SARS-CoV-2
What this study did
NCT04347031 · Burnasyan Federal Medical Biophysical Center
2020-04-08 – 2020-11-20 · Pneumonia, Viral, Respiratory Failure
What this study did
NCT04321616 · Oslo University Hospital
2020-03-28 – 2020-11 · SARS-CoV Infection, COVID 19, Acute Respiratory Distress Syndrome ARDS
What this study did
NCT04328961 · University of Washington
2020-03-31 – 2020-10-08 · COVID-19, Corona Virus Infection, SARS (Severe Acute Respiratory Syndrome), SARS-CoV-2
What this study did
NCT04349410 · The Camelot Foundation
2020-04-11 – 2020-09-14 · CoVid 19 Positive
What this study did
NCT04341870 · Assistance Publique - Hôpitaux de Paris
2020-04-11 – 2020-08 · COVID19, SARS-CoV-2 Infection
What this study did
NCT04353271 · University of South Alabama
2020-04-17 – 2020-07-08 · Covid 19, Corona Virus Infection
What this study did
NCT04353336 · Tanta University
2020-03-23 – 2020-07-01 · COVID-19, Coronavirus Infection
What this study did
Phase 2 (114)
Rheumatoid Arthritis
NCT02603146 · National Institute of Allergy and Infectious Diseases (NIAID)
2016-04-27 – 2022-11-01 · Healthy Participants, Rheumatoid Arthritis (RA) Prevention
What this study did
Systemic Lupus Erythematosus
NCT03030118 · Milton S. Hershey Medical Center
2017-12-28 – 2024-06-30 · Systemic Lupus Erythematosus
What this study did
NCT01946880 · National Institute of Allergy and Infectious Diseases (NIAID)
2013-11-20 – 2019-07-03 · Systemic Lupus Erythematosus, SLE
What this study did
Other / comorbidity
NCT06350630 · Centre Hospitalier Universitaire de Saint Etienne
2025-06-26 – 2030-12-31 · IgA Nephropathy
What this study did
NCT07750067 · Sun Yat-sen University
2026-04-01 – 2030-07-28 · Melanoma Metastatic, NRAS Mutation
What this study did
NCT04354649 · AHS Cancer Control Alberta
2021-09-16 – 2030-07 · Arthritis, Arthralgia
What this study did
NCT05733000 · Northwestern University
2023-03-08 – 2030-03-04 · Advanced Biliary Tract Carcinoma, Advanced Colorectal Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Lung Adenocarcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma, Advanced Pancreatic Carcinoma, Advanced Urothelial Carcinoma, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Metastatic Biliary Tract Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Lung Adenocarcinoma, Metastatic Ovarian Carcinoma, Metastatic Pancreatic Carcinoma, Metastatic Urothelial Carcinoma, Refractory Biliary Tract Carcinoma, Refractory Colorectal Carcinoma, Refractory Gastroesophageal Junction Adenocarcinoma, Refractory Lung Adenocarcinoma, Refractory Ovarian Carcinoma, Refractory Pancreatic Carcinoma, Refractory Urothelial Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
What this study did
NCT07825454 · Indiana University
2026-10-19 – 2029-12 · Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS), Joint Pain, Breast Cancer
What this study did
NCT06971744 · Medical University of South Carolina
2025-12-18 – 2029-06-18 · Ovarian Cancer
What this study did
NCT04523857 · Abramson Cancer Center at Penn Medicine
2021-11-01 – 2028-12 · Breast Cancer
What this study did
NCT07467252 · Ministry of Health, Saudi Arabia
2026-09 – 2028-06 · Pulmonary Tuberculosis
What this study did
NCT04841148 · Abramson Cancer Center at Penn Medicine
2021-06-01 – 2028-05 · Breast Cancer
What this study did
NCT07138898 · NYU Langone Health
2025-12-12 – 2028-01 · Rheumatic Disease
What this study did
NCT00977470 · Massachusetts General Hospital
2009-10 – 2027-12 · Non-small Cell Lung Cancer
What this study did
NCT07443436 · Assistance Publique - Hôpitaux de Paris
2026-11-01 – 2027-11-01 · Interstitial Lung Disease
What this study did
NCT06816810 · Ottawa Hospital Research Institute
2025-06-09 – 2027-09 · Parkinson&Amp;#39;s Disease
What this study did
NCT06467526 · Chang Gung Memorial Hospital
2024-09-10 – 2027-03-31 · Sudden Hearing Loss
What this study did
NCT03032406 · Abramson Cancer Center at Penn Medicine
2017-01-23 – 2027-01-01 · Breast Cancer Stage IIB
What this study did
NCT05041907 · University of Oxford
2021-09-30 – 2027-01 · COVID-19
What this study did
NCT06768294 · I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio
2025-01 – 2027-01 · Calcium Pyrophosphate Deposition Disease, Chondrocalcinosis
What this study did
NCT06519617 · Qingwen Tao
2024-07-13 – 2026-12-31 · Primary Sjögren Syndrome
What this study did
NCT05843188 · University Health Network, Toronto
2023-08-09 – 2026-12-24 · Metastatic Colorectal Cancer
What this study did
NCT06229340 · N.N. Petrov National Medical Research Center of Oncology
2023-10-03 – 2026-10-01 · RAS Mutation, Ras (Kras or Nras) Gene Mutation, Colorectal Cancer Recurrent, Pancreas Cancer, Lung Cancer, Melanoma, Refractory Cancer
What this study did
NCT05576896 · Northwestern University
2022-10-10 – 2026-04-20 · Stage IV Colorectal Cancer Positive for BRAF V600E Mutation, Colorectal Cancer, Colorectal Cancer Stage IV
What this study did
NCT05518110 · Cancer Trials Ireland
2023-05-31 – 2026-03-03 · Pancreatic Cancer
What this study did
NCT05689359 · University of Arizona
2024-06 – 2025-12-01 · Breast Cancer, Gynecologic Cancer, Early-stage Breast Cancer, Peripheral Neuropathy, Chemotherapy-induced Peripheral Neuropathy
What this study did
NCT04275778 · Assistance Publique - Hôpitaux de Paris
2021-07-09 – 2025-10-02 · Antiphospholipid Syndrome in Pregnancy, Anticoagulants
What this study did
NCT05113004 · Assistance Publique - Hôpitaux de Paris
2022-01-20 – 2025-10-01 · Primary Sjögren's Syndrome (pSS)
What this study did
NCT05647330 · Henan Cancer Hospital
2022-12-15 – 2025-10-01 · Hydroxychloroquine, Gemcitabine, Lung Neoplasms
What this study did
NCT04669197 · HonorHealth Research Institute
2020-12-01 – 2025-07-31 · Untreated Resectable Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma
What this study did
NCT03037437 · The University of Texas Health Science Center at San Antonio
2017-02-16 – 2025-06-27 · Hepatocellular Cancer
What this study did
NCT04937907 · Shanghai Children's Hospital
2021-09-08 – 2024-12-31 · Alport Syndrome, X-Linked
What this study did
NCT05013463 · University of Calgary
2021-10-01 – 2024-09-01 · Multiple Sclerosis, Secondary Progressive
What this study did
NCT05221320 · BioMed Valley Discoveries, Inc
2022-05-26 – 2024-07-14 · Tumor, Solid, Gastrointestinal Cancer
What this study did
NCT04335084 · ProgenaBiome
2020-06-22 – 2024-04-11 · COVID-19, Coronavirus Infection, Sars-CoV2, Corona Virus Infection, COVID, Coronavirus, Coronavirus-19, Coronavirus 19
What this study did
NCT04011410 · Patrick Hensley
2019-12-03 – 2024-03-08 · Prostate Cancer Recurrent
What this study did
NCT04334512 · ProgenaBiome
2020-06-22 – 2024-02-27 · COVID-19, Corona Virus Infection, Coronavirus-19, Sars-CoV2
What this study did
NCT04386057 · Kimberly Perez, MD
2020-05-27 – 2024-02-05 · Pancreatic Cancer, Advanced Cancer
What this study did
NCT03636152 · VA Office of Research and Development
2018-12-14 – 2024-01-31 · Chronic Kidney Disease, Cardiovascular Disease, Inflammation, Atherosclerosis, Aortic Stiffness
What this study did
NCT04527549 · ECOG-ACRIN Cancer Research Group
2021-06-01 – 2024-01-08 · Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Unresectable Melanoma
What this study did
NCT04735068 · Abramson Cancer Center at Penn Medicine
2021-04-09 – 2023-12-31 · Non-Small Cell Lung Cancer, KRAS Mutation-Related Tumors
What this study did
NCT04524702 · Emory University
2020-09-14 – 2023-06-06 · Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
What this study did
NCT04566133 · National Cancer Institute (NCI)
2022-02-15 – 2022-12-31 · Bile Duct Cancer, Biliary Cancer, Biliary Tract Neoplasms, Cholangiocarcinoma
What this study did
NCT03428945 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
2018-08-15 – 2022-10-31 · Type1 Diabetes Mellitus
What this study did
NCT05113810 · Ministry of Health Jordan
2022-03-20 – 2022-07-20 · 2019 Novel Coronavirus
What this study did
NCT03377179 · RedHill Biopharma Limited
2018-03-07 – 2022-06-21 · Cholangiocarcinoma, Cholangiocarcinoma Non-resectable, Cholangiocarcinoma, Perihilar, Cholangiocarcinoma, Extrahepatic, Cholangiocarcinoma, Intrahepatic
What this study did
NCT04341207 · Gustave Roussy, Cancer Campus, Grand Paris
2020-04-03 – 2022-04 · Cancer & COVID 19
What this study did
NCT04395768 · National Institute of Integrative Medicine, Australia
2020-09-09 – 2021-12-31 · COVID19
What this study did
NCT04860284 · Makerere University
2020-09-18 – 2021-12-01 · Covid19
What this study did
NCT04459702 · ProgenaBiome
2020-07 – 2021-12 · COVID, COVID-19, Corona Virus Infection, Coronavirus Infection, Coronavirus Sars-Associated as Cause of Disease Classified Elsewhere, Coronavirus-19, SARS-CoV 2, SARS Pneumonia
What this study did
Phase 1/2 (38)
Systemic Lupus Erythematosus
NCT02756546 · Cairo University
2014-09 – 2015-12 · Systemic Lupus Erythematosis
What this study did
Other / comorbidity
NCT05842174 · VA Office of Research and Development
2026-04-01 – 2030-10-15 · Hepatocellular Carcinoma
What this study did
NCT04911816 · West Virginia University
2021-07-16 – 2030-06 · Adenocarcinoma of the Pancreas
What this study did
NCT05036226 · Medical University of South Carolina
2022-03-03 – 2028-05-21 · Prostate Cancer Recurrent, Solid Tumor, Adult
What this study did
NCT03929211 · Wake Forest University Health Sciences
2021-05 – 2027-07 · Myelodysplastic Syndromes, Progressive Disease
What this study did
NCT03598595 · M.D. Anderson Cancer Center
2019-01-28 – 2027-05-31 · Recurrent Osteosarcoma, Refractory Osteosarcoma
What this study did
NCT04464759 · Ravi Amaravadi, MD
2020-10-21 – 2027-05-12 · Melanoma
What this study did
NCT04201457 · Pediatric Brain Tumor Consortium
2020-01-17 – 2026-12-31 · Low Grade Glioma (LGG) of Brain With BRAF Aberration, High Grade Glioma (HGG) of the Brain With BRAF Aberration, Low Grade Glioma of Brain With Neurofibromatosis Type 1
What this study did
NCT06328387 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2024-01-29 – 2026-03-01 · Advanced Breast Cancer, Metastatic Breast Cancer
What this study did
NCT06939582 · Xingchen Peng
2024-12-22 – 2025-06-20 · Radiation-induced Oral Mucositis
What this study did
NCT05119140 · Icahn School of Medicine at Mount Sinai
2022-06-10 – 2025-05 · Ulcerative Colitis (Disorder)
What this study did
NCT05953350 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2023-11-07 – 2024-12-31 · Inhibition of Autophagy Synergizes Anti-tumor Effect
What this study did
NCT04120883 · University of Michigan
2020-02-25 – 2024-08-05 · Retinitis Pigmentosa
What this study did
NCT03774472 · M.D. Anderson Cancer Center
2018-08-20 – 2024-04-17 · Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8
What this study did
NCT03513211 · St Vincent's Hospital, Sydney
2018-08-23 – 2023-10-30 · Prostate Cancer
What this study did
NCT04731051 · King Hussein Cancer Center
2022-10 – 2022-12 · 2019 Novel Coronavirus
What this study did
NCT03754179 · Universitair Ziekenhuis Brussel
2018-01-23 – 2022-07-01 · Melanoma
What this study did
NCT01506973 · Abramson Cancer Center at Penn Medicine
2011-12 – 2022-03 · Advanced Adenocarcinoma, Metastatic Adenocarcinoma
What this study did
NCT02257424 · Abramson Cancer Center at Penn Medicine
2014-10 – 2021-10 · Advanced BRAF Mutant Melanoma
What this study did
NCT04344457 · Perseverance Research Center, LLC
2020-04-16 – 2020-09-30 · COVID-19
What this study did
NCT04435808 · University of New Mexico
2020-04-14 – 2020-07-15 · COVID-19
What this study did
NCT03400254 · Abramson Cancer Center at Penn Medicine
2019-02-26 – 2019-11-12 · Breast Cancer
What this study did
NCT03081702 · University Health Network, Toronto
2017-07-25 – 2019-08-27 · Platinum-resistant Epithelial Ovarian Cancer
What this study did
NCT03275870 · Elena Gonzalez Brant, MD
2017-09-28 – 2019-06-30 · Hidradenitis Suppurativa, Hidradenitis, Acne Inversa, Boils, Follicular Occlusion Triad, Follicular Occlusion Tetrad
What this study did
NCT01550367 · Leonard Appleman
2012-03 – 2019-02 · Metastatic Renal Cell Carcinoma
What this study did
NCT02910076 · Hadassah Medical Organization
2016-10 – 2018-08 · Diabetes Type Two
What this study did
NCT01206530 · Abramson Cancer Center at Penn Medicine
2010-09 – 2017-09 · Rectal Cancer, Colon Cancer, Metastasis, Adenocarcinoma
What this study did
NCT01510119 · Abramson Cancer Center at Penn Medicine
2011-09 – 2017-01-05 · Metastatic Clear Cell Renal Cell Carcinoma
What this study did
NCT02475915 · SEARCH Research Foundation
2015-01 – 2016-03 · Acute HIV Infection
What this study did
NCT00809237 · National University Hospital, Singapore
2008-11 – 2014-11 · Non-small Cell Lung Cancer
What this study did
NCT01128296 · Amer Zureikat
2010-10 – 2014-07 · Pancreatic Cancer
What this study did
NCT00486603 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2007-10-29 – 2014-01 · Brain and Central Nervous System Tumors
What this study did
NCT00765765 · University of Medicine and Dentistry of New Jersey
2009-02 – 2011-12 · Breast Cancer
What this study did
NCT00728845 · University of Medicine and Dentistry of New Jersey
2008-06-16 – 2010-12-21 · Lung Cancer
What this study did
Phase 1 (51)
Other / comorbidity
NCT06408298 · Lionel.D.Lewis, MD
2026-01-06 – 2029-03 · Resectable Localized Prostate Cancer
What this study did
NCT07814339 · Rutgers, The State University of New Jersey
2026-09 – 2028-06 · Acute Myeloid Leukemia
What this study did
NCT04316169 · Medical College of Wisconsin
2021-10-21 – 2028-01 · Solid Tumor, Advanced Breast Cancer
What this study did
NCT04532346 · Children's Hospital of Fudan University
2024-09-01 – 2027-04 · Interstitial Lung Disease, Surfactant Dysfunction
What this study did
NCT01480154 · National Cancer Institute (NCI)
2011-11-23 – 2027-03-31 · Advanced Malignant Solid Neoplasm, Stage III Cutaneous Melanoma AJCC v7, Stage III Prostate Cancer AJCC v7, Stage III Renal Cell Cancer AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Prostate Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7
What this study did
NCT05365893 · Fox Chase Cancer Center
2021-10-20 – 2026-12-31 · Pancreatic Ductal Adenocarcinoma
What this study did
NCT05083780 · Changhoon Yoo
2021-11-30 – 2026-12-30 · Pancreatic Cancer
What this study did
NCT04132505 · M.D. Anderson Cancer Center
2019-10-22 – 2026-03-24 · Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
What this study did
NCT03825289 · University of Utah
2019-01-30 – 2025-08-03 · Metastatic Pancreatic Carcinoma, Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Unresectable Pancreatic Carcinoma
What this study did
NCT06776445 · First Affiliated Hospital of Chongqing Medical University
2024-01-05 – 2025-07-31 · Rosacea, Rosacea Subtype 1 (Erythematotelangiectatic)
What this study did
NCT04787991 · Cancer Insight, LLC
2021-08-09 – 2025-07-31 · Metastatic Pancreatic Adenocarcinoma
What this study did
NCT04873895 · Abramson Cancer Center at Penn Medicine
2022-01-24 – 2024-04-25 · Colorectal Neoplasms Malignant
What this study did
NCT00813423 · National Cancer Institute (NCI)
2010-02-19 – 2023-07-18 · Adult Solid Neoplasm
What this study did
NCT04348474 · Azidus Brasil
2020-04-20 – 2023-07 · Covid-19
What this study did
NCT04329572 · Azidus Brasil
2020-04-23 – 2023-06-30 · COVID-19
What this study did
NCT01023737 · The University of Texas Health Science Center at San Antonio
2009-11 – 2023-01-08 · Malignant Solid Tumour
What this study did
NCT05237843 · Ain Shams University
2022-03-01 – 2023-01 · Recurrent Pregnancy Loss
What this study did
NCT04145297 · University of Utah
2020-03-17 – 2022-08-18 · Gastrointestinal Neoplasms
What this study did
NCT04973566 · Janssen Research & Development, LLC
2021-08-31 – 2022-05-27 · Healthy
What this study did
NCT04163107 · Norwegian University of Science and Technology
2020-01-07 – 2021-12-28 · Multiple Myeloma
What this study did
NCT04590274 · International Brain Research Foundation
2020-11 – 2021-12 · Covid19, SARS (Severe Acute Respiratory Syndrome)
What this study did
NCT04340349 · Instituto Nacional de Rehabilitacion
2021-02-01 – 2021-06-30 · Hydroxychloroquine, Antimalarials, Enzyme Inhibitors, Antirheumatic Agents
What this study did
NCT01266057 · M.D. Anderson Cancer Center
2011-04-28 – 2021-02-11 · Advanced Cancers
What this study did
NCT03015324 · Peng Wang, MD PhD
2017-08-08 – 2021-02-02 · Solid Tumor
What this study did
NCT04497519 · University Medical Center Groningen
2020-09-15 – 2020-11-01 · Covid19
What this study did
NCT04461353 · Pulmoquine Therapeutics, Inc
2020-06-25 – 2020-08-17 · Severe Acute Respiratory Syndrome Coronavirus 2
What this study did
NCT04351620 · University of Chicago
2020-04-20 – 2020-06-10 · COVID-19
What this study did
NCT03215264 · Abramson Cancer Center at Penn Medicine
2017-10-02 – 2020-06-01 · Colorectal Cancer
What this study did
NCT04333654 · Sanofi
2020-04-12 – 2020-05-26 · Coronavirus Infection
What this study did
NCT04323631 · Rambam Health Care Campus
2020-04-30 – 2020-04-30 · COVID-19
What this study did
NCT02232243 · Peng Wang, MD PhD
2015-07 – 2018-12-01 · Solid Tumor
What this study did
NCT02631252 · Alison Sehgal, MD, MS
2016-08-18 – 2017-10-02 · Leukemia, Acute Myelogenous
What this study did
NCT01897116 · Abramson Cancer Center at Penn Medicine
2013-06 – 2016-10-05 · Melanoma
What this study did
NCT01144169 · University of Pittsburgh
2010-10 – 2016-09 · Renal Cell Carcinoma
What this study did
NCT02124681 · University of Pittsburgh
2014-04 – 2016-08 · Insulin Resistance
What this study did
NCT01689987 · OHSU Knight Cancer Institute
2012-09 – 2016-04 · Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
What this study did
NCT02421575 · Rutgers, The State University of New Jersey
2012-07 – 2016-02-26 · Prostate Carcinoma
What this study did
NCT01634893 · The University of Texas Health Science Center at San Antonio
2012-06 – 2015-12 · Refractory or Relapsed Solid Tumors
What this study did
NCT02414776 · Western Regional Medical Center
2014-07 – 2015-11 · Estrogen Receptor Positive Breast Cancer
What this study did
NCT01687179 · Brigham and Women's Hospital
2012-09 – 2015-08 · Lymphangioleiomyomatosis
What this study did
NCT01495403 · Mayo Clinic
2011-12 – 2015-04 · Liver Cirrhosis, Muscle Cramps
What this study did
NCT01232660 · St Stephens Aids Trust
2010-10 – 2014-08 · HIV Infection
What this study did
NCT01417403 · Virginia Commonwealth University
2011-08 – 2014-07 · Bone Metastases, Unspecified Adult Solid Tumor, Protocol Specific
What this study did
NCT00909831 · Abramson Cancer Center at Penn Medicine
2008-10 – 2013-11 · Unspecified Adult Solid Tumor, Protocol Specific
What this study did
NCT00714181 · Abramson Cancer Center at Penn Medicine
2008-06 – 2013-06 · Unspecified Adult Solid Tumor, Protocol Specific
What this study did
NCT00962845 · Rutgers, The State University of New Jersey
2010-09 – 2013-05-30 · Melanoma (Skin)
What this study did
NCT01026844 · Massachusetts General Hospital
2007-07 – 2012-11 · Non-small Cell Lung Cancer
What this study did
NCT01396200 · Abramson Cancer Center at Penn Medicine
2011-06 – 2012-10 · Myeloma
What this study did
NCT00568880 · Abramson Cancer Center at Penn Medicine
2010-09-08 – 2011-06-22 · Multiple Myeloma and Plasma Cell Neoplasm
What this study did
NCT00311883 · Vanderbilt University
2006-03 – 2007-12 · Cystic Fibrosis
What this study did
Phase 4 (48)
Rheumatoid Arthritis
NCT05626348 · Qilu Hospital of Shandong University
2021-12-22 – 2026-12-31 · Arthritis, Rheumatoid
What this study did
NCT02374021 · Brigham and Women's Hospital
2016-07 – 2021-05 · Arthritis, Rheumatoid
What this study did
NCT03449758 · Sanofi
2018-03-05 – 2019-07-31 · Rheumatoid Arthritis
What this study did
NCT02451748 · University of Illinois at Chicago
2015-08 – 2017-12 · Rheumatoid Arthritis
What this study did
NCT02644499 · Jawaharlal Institute of Postgraduate Medical Education & Research
2015-12-31 – 2017-09-15 · Rheumatoid Arthritis
What this study did
NCT00259610 · University of Alabama at Birmingham
2004-05 – 2009-06 · Rheumatoid Arthritis
What this study did
NCT00422227 · Wyeth is now a wholly owned subsidiary of Pfizer
2007-06 – 2009-03 · Rheumatoid Arthritis
What this study did
Systemic Lupus Erythematosus
NCT05666336 · Fen Li
2022-12-31 – 2024-06-30 · Systemic Lupus Erythematosus
What this study did
NCT03122431 · University of Sao Paulo General Hospital
2017-06-05 – 2021-03-30 · Systemic Lupus Erythematosus (SLE), Juvenile SLE, Cutaneous Lupus
What this study did
Other / comorbidity
NCT07352566 · University of California, San Francisco
2026-08-01 – 2030-06-01 · Psoriasis, Atopic Dermatitis
What this study did
NCT06676384 · Christian Medical College, Vellore, India
2025-02-15 – 2029-08 · IgA Nephropathy, Renal Insufficiency, Chronic, IgA Vasculitis, IGA Glomerulonephritis
What this study did
NCT05841758 · Hospices Civils de Lyon
2024-07-30 – 2029-07-01 · Sarcoidosis, Pulmonary
What this study did
NCT05126147 · National Taiwan University Hospital
2022-03-21 – 2027-06-30 · Graves Ophthalmopathy
What this study did
NCT04316494 · Guy's and St Thomas' NHS Foundation Trust
2020-12-17 – 2025-05-15 · ANCA Associated Vasculitis, Microscopic Polyangiitis, Churg-Strauss Syndrome, Wegener Granulomatosis
What this study did
NCT04316377 · University Hospital, Akershus
2020-03-25 – 2025-03-03 · Corona Virus Infection
What this study did
NCT03025087 · Duke University
2017-06-19 – 2024-04-19 · Individuals Undergoing Cardiac and General Surgery
What this study did
NCT04624269 · Shanghai First Maternity and Infant Hospital
2020-12-01 – 2023-02-01 · Antiphospholipid Syndrome, Recurrent Miscarriage
What this study did
NCT04077957 · Nanfang Hospital, Southern Medical University
2019-10-07 – 2022-07-02 · Ankylosing Spondylitis, Spondyloarthritis
What this study did
NCT04382625 · Kootenai Health
2020-10 – 2022-06-01 · SARS-CoV-2 Pneumonia, COVID-19
What this study did
NCT04334967 · Providence Health & Services
2020-03-30 – 2022-05-27 · COVID-19, Corona Virus Infection, SARS-CoV-2, 2019-nCoV, 2019 Novel Coronavirus
What this study did
NCT04466540 · Hospital Alemão Oswaldo Cruz
2020-05-12 – 2021-09-28 · COVID-19
What this study did
NCT04330495 · Instituto de Investigación Marqués de Valdecilla
2020-04-06 – 2021-08-27 · COVID 19, Immunomediated Inflammatory Disease in Treatment With Biological Agents and / or Jak Inhibitors
What this study did
NCT04779047 · October 6 University
2020-10-01 – 2021-04-05 · Covid19, Pneumonia
What this study did
NCT04746365 · Elaraby Hospital
2020-12-06 – 2021-02-06 · Covid19
What this study did
NCT04341493 · Hugo Mendieta Zeron
2020-04-06 – 2020-12-30 · Coronavirus Infection
What this study did
NCT04429867 · WellStar Health System
2020-05-07 – 2020-12-07 · COVID-19
What this study did
NCT04652648 · Bryn Mawr Hospital
2020-05-27 – 2020-11-15 · Covid19, Hydroxychloroquine, Coronavirus Infection, Transmission, Prophylaxis
What this study did
NCT05110651 · Nicholas Carlson
2020-04-10 – 2020-10-01 · COVID-19, End Stage Renal Disease
What this study did
NCT04005781 · Universitaire Ziekenhuizen KU Leuven
2019-10-01 – 2020-10-01 · Obesity
What this study did
NCT04370782 · St. Francis Hospital, New York
2020-04-28 – 2020-09-30 · COVID-19
What this study did
NCT04346667 · Government of Punjab, Specialized Healthcare and Medical Education Department
2020-04-14 – 2020-08-30 · SARS-CoV-2, Coronavirus Infection, Asymptomatic Condition, COVID-19
What this study did
NCT04351191 · Government of Punjab, Specialized Healthcare and Medical Education Department
2020-04-15 – 2020-08-30 · Sars-CoV2, Symptomatic Condition, Covid-19
What this study did
NCT03592823 · First Affiliated Hospital of Harbin Medical University
2018-08-01 – 2020-08-01 · Atrial Fibrillation
What this study did
NCT04355026 · General and Teaching Hospital Celje
2020-04-10 – 2020-07-31 · Covid-19
What this study did
NCT04351919 · Abderrahmane Mami Hospital
2020-05-05 – 2020-07-15 · Patients With COVID19
What this study did
NCT04161339 · Instituto de Cardiologia do Rio Grande do Sul
2019-07-01 – 2020-06-30 · Cardiovascular Diseases, Endothelial Dysfunction, Sleep Apnea, Atherosclerosis, Coronary Artery Disease
What this study did
NCT04362332 · UMC Utrecht
2020-04-14 – 2020-06-08 · COVID-19
What this study did
NCT04350671 · Shahid Beheshti University of Medical Sciences
2020-04-15 – 2020-04-24 · COVID-19
What this study did
NCT04350684 · Shahid Beheshti University of Medical Sciences
2020-04-15 – 2020-04-24 · COVID-19
What this study did
NCT02648464 · Helsinki University Central Hospital
2016-02-01 – 2019-12-31 · Myocardial Infarction, Acute Coronary Syndrome, Inflammation, Hydroxychloroquine, Antirheumatic Agents, Cardiovascular Diseases
What this study did
NCT04005768 · Universitaire Ziekenhuizen KU Leuven
2019-08-01 – 2019-10-01 · Obesity
What this study did
NCT02874287 · First Affiliated Hospital Xi'an Jiaotong University
2017-10-08 – 2019-06-01 · Coronary Artery Disease
What this study did
NCT02765594 · Peking Union Medical College Hospital
2016-06 – 2019-06 · Primary IgA Nephropathy
What this study did
NCT03229746 · Assiut University
2017-08-01 – 2018-06-01 · Immune Thrombocytopenia
What this study did
NCT02351752 · LLiu
2015-01 – 2015-10 · Primary IgA Nephropathy
What this study did
NCT01326533 · University of Pittsburgh
2011-03 – 2014-12 · Pre-diabetes
What this study did
NCT01207739 · Radboud University Medical Center
2010-09 – 2014-10 · Lyme Disease, Borrelia Infection
What this study did
NCT00176982 · Hordinsky, Maria K., MD
2002-04 – 2008-01 · Alopecia Areata
What this study did
Early phase / not applicable (38)
Rheumatoid Arthritis
NCT03085940 · Universitas Indonesia
2017-01-20 – 2017-09-30 · Rheumatoid Arthritis
What this study did
NCT00405275 · US Department of Veterans Affairs
2007-07 – 2012-05 · Rheumatoid Arthritis
What this study did
Systemic Lupus Erythematosus
NCT07675291 · Nanfang Hospital, Southern Medical University
2026-06 – 2028-12-31 · Lupus Nephritis
What this study did
Other / comorbidity
NCT06652113 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2024-11-15 – 2037-03 · Recurrent Pregnancy Loss, Euthyroid With Thyroid Antibodies
What this study did
NCT06479291 · Yunfeng Cheng
2024-07 – 2026-12 · Immune Thrombocytopenia With Positive ANA Antibodies
What this study did
NCT06479304 · Yunfeng Cheng
2024-04-24 – 2026-12 · Immune Thrombocytopenia With Positive ANA Antibodies
What this study did
NCT06479317 · Yunfeng Cheng
2024-04-24 – 2026-12 · Immune Thrombocytopenia With Positive ANA Antibodies
What this study did
NCT06319560 · National University of Malaysia
2024-03-24 – 2026-06-01 · Diabetes in Pregnancy, Type 2 Diabetes
What this study did
NCT04310462 · University of California, San Francisco
2017-02-01 – 2024-02-28 · Rheumatic Diseases
What this study did
NCT06432101 · Senyue Zhang
2023-01-01 – 2023-12-31 · Primary Sjögren's Syndrome
What this study did
NCT04755322 · Assiut University
2021-03-01 – 2023-07-30 · Preeclampsia
What this study did
NCT04228263 · Assiut University
2020-01-01 – 2023-07-08 · Unexplained Recurrent Miscarriage
What this study did
NCT03671174 · RenJi Hospital
2019-08-02 – 2023-02 · Undifferentiated Connective Tissue Disease, Recurrent Pregnancy Loss
What this study did
NCT03979651 · Hospices Civils de Lyon
2019-10-15 – 2023-01-03 · Metastatic NRAS Melanoma
What this study did
NCT02026232 · Washington University School of Medicine
2012-03 – 2022-12-15 · Type 2 Diabetes Mellitus
What this study did
NCT04438837 · Rambam Health Care Campus
2020-07 – 2022-06 · Coronavirus Disease 2019 (COVID-19), Post-Exposure Prophylaxis
What this study did
NCT04374903 · King Hussein Cancer Center
2022-04-01 – 2022-04-01 · COVID-19 Patients
What this study did
NCT04303507 · University of Oxford
2020-04-29 – 2022-03-22 · COVID19, Coronavirus, Acute Respiratory Illnesses
What this study did
NCT04394182 · Fundacion GenesisCare
2020-04-21 – 2022-03-21 · Pneumonia, Viral, Cytokine Storm
What this study did
NCT05311813 · Beni-Suef University
2021-06-01 – 2021-12-30 · COVID-19 Pandemic
What this study did
NCT04371926 · Texas Cardiac Arrhythmia Research Foundation
2020-06 – 2021-07 · COVID-19
What this study did
NCT04392973 · King Abdullah International Medical Research Center
2020-05-21 – 2021-04-26 · COVID19
What this study did
NCT05024006 · University of the Philippines
2020-04-23 – 2021-04-17 · Covid19
What this study did
NCT04384458 · Nucleo De Pesquisa E Desenvolvimento De Medicamentos Da Universidade Federal Do Ceara
2020-07-20 – 2021-04 · Coronavirus Infections
What this study did
NCT03400865 · Zhebao Wu
2018-10-25 – 2020-12-30 · Resistance, Disease, Prolactinoma
What this study did
NCT04354597 · King Hussein Cancer Center
2020-05-01 – 2020-10-15 · COVID-19
What this study did
NCT04370015 · Services Institute of Medical Sciences, Pakistan
2020-05-15 – 2020-10-15 · SARS-CoV-2, Healthcare Workers
What this study did
NCT04466280 · Baqiyatallah Medical Sciences University
2020-08-12 – 2020-09-21 · COVID-19
What this study did
NCT04477083 · Mansoura University
2020-07-15 – 2020-08-15 · Covid19, Hydroxychloroquine Adverse Reaction
What this study did
NCT04423991 · Dascena
2020-03-10 – 2020-06-04 · COVID-19, Coronavirus, Mortality
What this study did
NCT04384380 · Taoyuan General Hospital
2020-04-01 – 2020-05-31 · Coronavirus Infection
What this study did
NCT04376814 · Baqiyatallah Medical Sciences University
2020-03-29 – 2020-05-25 · COVID-19, Favipiravir, Kaletra, Hydroxychloroquine, Lopinavir/Ritonavir
What this study did
NCT04153201 · National and Kapodistrian University of Athens
2013-01-15 – 2019-10-16 · Antiphospholipid Syndrome
What this study did
NCT04022421 · Assiut University
2018-10-01 – 2019-10 · Behcet's Syndrome, Vascular Type
What this study did
NCT02079077 · University of Manitoba
2014-04 – 2018-01-01 · HIV
What this study did
NCT02126683 · National Taiwan University Hospital
2014-04 – 2016-09 · Hashimoto's Thyroiditis
What this study did
NCT01760421 · National Taiwan University Hospital
2011-10 – 2013-08 · Hashimoto Thyroiditis
What this study did
NCT01073852 · Vanderbilt University
2011-06 – 2012-06 · Chronic Urticaria
What this study did
Used as active comparator (20)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (4)
Other / comorbidity
NCT04411433 · Ministry of Health, Turkey
2020-05-08 – 2021-06-01 · Sars-CoV2, COVID-19
What this study did
NCT04338698 · Shehnoor Azhar
2020-04-22 – 2020-11-22 · COVID 19
What this study did
NCT04339816 · Frantisek Duska, MD, PhD
2020-05-13 – 2020-11-04 · COVID-19, Respiratory Failure
What this study did
Phase 2/3 (1)
Other / comorbidity
NCT05678335 · Peking Union Medical College Hospital
2023-02 – 2024-03 · Sjogren Syndrome With Other Organ Involvement
What this study did
Phase 2 (6)
Rheumatoid Arthritis
NCT05942911 · Incannex Healthcare Ltd
2023-11-22 – 2025-10-28 · Rheumatoid Arthritis
What this study did
Other / comorbidity
NCT07557927 · Kunming Pharmaceuticals, Inc.
2026-04-30 – 2028-09-30 · Discoid Lupus Erythematosus
What this study did
NCT06862284 · Peking University People's Hospital
2025-03-10 – 2027-08-31 · Primary Sjögren's Syndrome (pSS)
What this study did
NCT05016297 · Peking Union Medical College Hospital
2022-07-14 – 2024-11-22 · Sjogren's Syndrome
What this study did
NCT04501965 · Institute for Research and Development of Medicinal and Food Plants of Guinea
2020-06-01 – 2020-09-30 · Covid19
What this study did
NCT04307693 · Asan Medical Center
2020-03-11 – 2020-04-30 · COVID-19
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT04390152 · BioXcellerator
2020-01-13 – 2022-03-03 · Acute Respiratory Distress Syndrome
What this study did
Phase 4 (4)
Rheumatoid Arthritis
NCT03813771 · University of Leeds
2019-03 – 2023-02 · Rheumatoid Arthritis
What this study did
NCT02433184 · University of Leeds
2011-07 – 2019-07 · Rheumatoid Arthritis
What this study did
Other / comorbidity
NCT04435587 · Mahidol University
2020-07-13 – 2021-11 · Asymptomatic Infections, SARS-CoV2 Infection
What this study did
NCT04715295 · Yaounde Central Hospital
2020-10-05 – 2021-09-05 · COVID-19
What this study did
Early phase / not applicable (4)
Rheumatoid Arthritis
NCT04569890 · RenJi Hospital
2020-12-01 – 2023-12-01 · Rheumatoid Arthritis, Pregnancy Related
What this study did
Other / comorbidity
NCT07343635 · The Fourth Affiliated Hospital of Zhejiang University School of Medicine
2026-02-01 – 2027-07-01 · Erythematotelangiectatic Rosacea
What this study did
NCT04668469 · Benha University
2020-06-08 – 2020-10-30 · Covid19
What this study did
NCT04349592 · Hamad Medical Corporation
2020-04-14 – 2020-08-30 · Covid19
What this study did
Appears in other studies (9)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (2)
Rheumatoid Arthritis
Other / comorbidity
NCT04405921 · Centre Hôpital Universitaire Farhat Hached
2020-07 – 2021-03 · SARS-CoV-2 Pneumonia, COVID-19
What this study did
Phase 2/3 (1)
Other / comorbidity
NCT04573153 · ScandiBio Therapeutics AB
2020-09-21 – 2022-05-05 · COVID-19
What this study did
Phase 2 (2)
Other / comorbidity
NCT04373044 · University of Southern California
2020-05-01 – 2021-05-12 · Symptomatic COVID-19 Infection Laboratory-Confirmed
What this study did
NCT04390061 · Università Politecnica delle Marche
2020-06 – 2020-10 · Pneumonitis, Interstitial, COVID-19
What this study did
Phase 4 (3)
Other / comorbidity
NCT04338906 · Heinrich-Heine University, Duesseldorf
2020-05 – 2021-12 · COVID
What this study did
NCT04359615 · Shahid Beheshti University of Medical Sciences
2020-04-20 – 2020-05-05 · COVID-19
What this study did
NCT04359316 · Shahid Beheshti University of Medical Sciences
2020-04-20 – 2020-05-05 · COVID-19
What this study did
Early phase / not applicable (1)
Other / comorbidity
NCT04380818 · Grupo de Investigación Clínica en Oncología Radioterapia
2020-06-05 – 2021-11-01 · Pneumonia, Viral
What this study did

Competitive landscape

This drug's own stage for Rheumatoid Arthritis: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Hydroxychloroquine: this drugApprovedSmall moleculeAutophagy/lysosomal acidificationnot yet gradedNo reviewed efficacy summary in this indication
Abatacept (Orencia)ApprovedProtein / enzyme therapeuticCD80/CD86 (CTLA-4-Ig), Selective T Cell Costimulation Modulator, CD80/CD86 (B7-1/B7-2) on antigen-presenting cellsReliable signal
NCT00048568: Number of American College of Rheumatology 20 (ACR 20) Responders at Day 169 (Day 169): ABA + MTX DB 288/424 (67.9%) vs MTX + Placebo DB 85/214 (39.7%)
NCT00048581: Double-blind Period (DB); Number of Participants With American College of Rheumatology (ACR) 20 Response at Day 169 (Day 169): Abatacept (ABA) 129/256 (50.4%) vs Placebo (PLA) 26/133 (19.5%)
Adalimumab (Humira)ApprovedMonoclonal antibodyTNF-alphaReliable signal
NCT00195702: Primary 1, ACR20 at week 24: 63% (40 mg every other week) and 61% (20 mg weekly) vs 30% placebo, all with methotrexate (P<=0.001 for each), met. Primary 2, change in modified total Sharp score at week 52: 0.1 and 0.8 vs 2.7 (P<=0.001 for each), met. Primary 3, change in HAQ disability index at week 52: -0.59 and -0.61 vs -0.25 (P<=0.001 for each), met.
Adalimumab-Aacf (Idacio)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Aaty (Yuflyma)ApprovedMonoclonal antibodyTNF-alphaPartial signal
NCT03789292: ACR20 response at week 24, CT-P17 vs EU-adalimumab (ITT): 82.7% (268/324) in both groups; treatment difference 95% CI -5.94 to 5.94 (margin -15 to 15%) and 90% CI -4.98 to 4.98 (margin -12 to 15%), both within the predefined equivalence margins (Kay 2021, Arthritis Res Ther).
Adalimumab-Adaz (Hyrimoz)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Adbm (Cyltezo)ApprovedMonoclonal antibodyTNF-alphaReliable signalNo reviewed efficacy summary in this indication
Adalimumab-Afzb (Abrilada)ApprovedMonoclonal antibodyTNF-alphaReliable signal
NCT02480153: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12: Period 1 (Week 12): Period 1: PF-06410293 68.35% vs Period 1: Adalimumab-EU 71.33%
Adalimumab-Aqvh (Yusimry)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Atto (Amjevita)ApprovedMonoclonal antibodyTNF-alphaReliable signalFeatured results are non-efficacy only in this race
Adalimumab-Bwwd (Hadlima)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Fkjp (Hulio)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Ryvk (Simlandi)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
AnakinraApprovedProtein / enzyme therapeuticInterleukin-1 Receptor AntagonistWeak signalNo reviewed efficacy summary in this indication
Baricitinib (Olumiant)ApprovedSmall moleculeJAK, JAK1/2Reliable signal
NCT02265705: ACR20 response at Week 12 (primary endpoint, 290 randomized, 145 per arm): 58.6% baricitinib 4mg vs 28.3% placebo (OR 4.1, 95% CI 2.5-6.9; p=0.001)
NCT01710358: ACR20 response at Week 12 (primary endpoint): 70% baricitinib 4mg vs 40% placebo (P<0.001)
BAT1806 (Tofidence)ApprovedMonoclonal antibodyIL-6 receptorPartial signal
NCT03830203: ACR20 response rate at week 24: 67.9% reference tocilizumab vs 69.9% BAT1806/BIIB800; treatment difference 1.9% (90% CI -4.0 to 7.9), within predefined equivalence margins
Certolizumab Pegol (Cimzia)ApprovedAntibody fragmentTNF-alphaWeak signalFeatured results are non-efficacy only in this race
CT-P47 (tocilizumab) (Avtozma)ApprovedMonoclonal antibodyIL-6R antagonistReliable signal
NCT05489224: Mean Change From Baseline in Disease Activity Score 28 (DAS28) Using Erythrocyte Sedimentation Rate (ESR) at Week 24 (Week 24): CT-P47 -3.77 units on a scale (Standard Error 0.12) vs RoActemra -3.67 units on a scale (Standard Error 0.118)
NCT05725434: 12-week, single-arm, open-label Phase 3 usability study: Post-Self-Injection Assessment Questionnaire (POST-SIAQ) domain scores at Week 2 exceeded 8/10 for all domains except self-confidence (7.11) and satisfaction with self-injection (7.98); the study is reported to have met its primary usability endpoint, with no autoinjector malfunctions and no new safety signals.
Etanercept (Enbrel)ApprovedProtein / enzyme therapeuticTNF-alpha, TNF-alpha / TNF-beta (lymphotoxin-alpha)Partial signal
NCT03780959: Percentage of Participants With Disease Flare in Part 2 (End of part 1 (day 90) and months 4 to 7): Part 2: Etanercept 0.4 mg/kg 28% vs Part 2: Placebo 81%
Golimumab (Simponi)ApprovedMonoclonal antibodyTNF-alphaPartial signal
NCT00264550: Co-primary 1, ACR20 response at week 14 vs placebo plus methotrexate (44/133, 33.1%): combined golimumab plus methotrexate 99/178 (55.6%), p<0.001, the prespecified primary test, met; golimumab 50 mg plus methotrexate 49/89 (55.1%), p=0.001; golimumab 100 mg plus methotrexate 50/89 (56.2%), p<0.001. Co-primary 2, median HAQ improvement at week 24 vs placebo plus methotrexate (0.125): combined golimumab plus methotrexate 0.4375, p<0.001, met; 50 mg plus methotrexate 0.375, p<0.001; 100 mg plus methotrexate 0.500, p<0.001. Golimumab 100 mg alone vs placebo plus methotrexate (for ACR20, tested only after a positive primary test): ACR20 59/133 (44.4%), p=0.059; HAQ 0.125, p=0.240; not significant.
NCT00264537: ACR50 response at Week 24: placebo+MTX 47/160 vs combined golimumab+MTX (50mg or 100mg)+MTX 122/318; CMH p=0.053. Individually: golimumab 50mg+MTX 64/159 vs placebo+MTX 47/160, p=0.042; golimumab 100mg+MTX 58/159 vs placebo+MTX, p=0.177.
Infliximab (Remicade)ApprovedMonoclonal antibodyTNF-alphaReliable signalNo reviewed efficacy summary in this indication
Infliximab-Abda (Renflexis)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Infliximab-Axxq (Avsola)ApprovedMonoclonal antibodyTNF-alphaPartial signalFeatured results are non-efficacy only in this race
Infliximab-Dyyb (Inflectra)ApprovedMonoclonal antibodyTNF-alphaReliable signalFeatured results are pharmacokinetic only in this race
Infliximab-Qbtx (Ixifi)ApprovedMonoclonal antibodyTNF-alphaReliable signal
NCT02222493: Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 14: Period 1 (Week 14): Period 1: PF-06438179 198/324 (61.1%) vs Period 1: Infliximab-EU Remicade (INX) 207/326 (63.5%)
MethotrexateApprovedSmall moleculeDihydrofolate reductase (DHFR), Folate Analog Metabolic InhibitorPartial signal
NCT01185301: DAS28(CRP) < 3.2 at week 26 with adalimumab plus methotrexate 2.5, 5, 10 or 20 mg/week: 42.9%, 44.0%, 56.6% and 60.2% (n=98 to 100 per arm); statistically significant increasing trend with dose (Burmester et al., Ann Rheum Dis 2015).
MethylprednisoloneApprovedSmall moleculeGlucocorticoid receptor agonistnot yet gradedNo reviewed efficacy summary in this indication
PF-05280586ApprovedBiologic (subtype unspecified)CD20Partial signalFeatured results are pharmacokinetic only in this race
Repository Corticotropin (Acthar Gel)ApprovedPeptideMelanocortin receptors (primarily MC2R on the adrenal cortex), Melanocortin 2 receptor (MC2R) (agonist)not yet gradedNo reviewed efficacy summary in this indication
Rituximab (Rituxan)ApprovedMonoclonal antibodyCD20, CD20-directed Cytolytic AntibodyReliable signal
NCT00299130: Percentage of Participants With American College of Rheumatology (ACR) 20 Response at Week 24 (Baseline and Week 24): Rituximab 2 x 0.5 g + MTX 54.5% | Rituximab 2 x 1.0 g + MTX 50.6% vs Placebo + MTX 23.3%
NCT00468546: ACR20 response at week 24: 51.3% (153/298) with rituximab + methotrexate vs 17.9% (36/201) with placebo + methotrexate.
Rituximab-Abbs (Truxima)ApprovedMonoclonal antibodyCD20Reliable signal
NCT02149121: Primary efficacy: DAS28-CRP change from baseline -2.11 with CT-P10 vs -2.10 with reference products; treatment difference -0.01 (90% CI -0.22 to 0.20), with an equivalence margin of ±0.50. Primary PK AUC0-last ratio: 97.07% (CT-P10/Rituxan; 90% CI 88.08% to 106.99%) and 94.18% (CT-P10/MabThera; 90% CI 85.40% to 103.86%).
SarilumabApprovedMonoclonal antibodyIL-6 receptorReliable signal
NCT02332590: DB Period: Change From Baseline in Disease Activity Score for 28 Joints - Erythrocyte Sedimentation Rate (DAS28-ESR) Score at Week 24 (Baseline, Week 24): Sarilumab 200 mg/Sarilumab 200 mg -3.28 units on a scale (Standard Error 0.105) vs Adalimumab 40 mg/Sarilumab 200 mg -2.2 units on a scale (Standard Error 0.106)
NCT01061736: Part A: Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 12 (Baseline to Week 12): Part A: SAR 100 mg qw 62% | Part A: SAR 150 mg qw 72% | Part A: SAR 100 mg q2w 49% | Part A: SAR 150 mg q2w 66.7% | Part A: SAR 200 mg q2w 65.4% vs Part A: Placebo qw 46.2%
SulfasalazineApprovedSmall moleculeAminosalicylatenot yet gradedNo reviewed efficacy summary in this indication
Tocilizumab (Actemra / RoActemra)ApprovedMonoclonal antibodyIL-6 receptorReliable signal
NCT03155347: ACR20 response at Week 24: tocilizumab+methotrexate 52.9% (72/136) vs methotrexate alone 25.0% (17/68), difference 27.9pp (95% CI 14.7-41.2), P<.001; tocilizumab monotherapy 50.0% (68/136) vs methotrexate alone 25.0%, difference 25.0pp (95% CI 11.7-38.3), P<.001
NCT01232569: Percentage of Patients With an American College of Rheumatology 20 (ACR20) Response at Week 24 (Baseline to Week 24): Tocilizumab 162 mg sc 60.9% (95% CI 56.3 to 65.4) vs Placebo sc 31.5% (95% CI 25.4 to 37.7)
Tofacitinib (Xeljanz)ApprovedSmall moleculeJAK, JAK1/JAK3Weak signalFeatured results are non-efficacy only in this race
Upadacitinib (Rinvoq)ApprovedSmall moleculeJAK, JAK1Reliable signal
NCT03086343: Change from baseline DAS28-CRP at week 12: -2.52 (95% CI -2.66 to -2.37) upadacitinib vs -2.00 (95% CI -2.14 to -1.85) abatacept; upadacitinib met primary non-inferiority and key secondary superiority endpoints.
NCT02706873: Co-primary endpoints: ACR50 at Week 12 -- upadacitinib 15mg 52% (95% CI 47-58), 30mg 56% (95% CI 51-62), MTX 28% (95% CI 23-33), P<0.001 for both doses vs MTX. DAS28-CRP<2.6 at Week 24 -- upadacitinib 15mg 48% (95% CI 43-54), 30mg 50% (95% CI 45-56), MTX 19% (95% CI 14-23), P<0.001 for both doses vs MTX
AcellbiaPhase 3Monoclonal antibodyCD20Reliable signal
NCT02744196: ACR20 response at Week 24 (ALTERRA trial, N=159): Acellbia+MTX 65.7% vs Placebo+MTX 29.4% (p<0.0001); difference 36.3% (95% CI 19.27-53.28%)
Filgotinib (Jyseleca)Phase 3Small moleculeJAK, JAK1Reliable signal
NCT02889796: ACR20 at week 12 (primary endpoint): FIL200 76.6% vs placebo 49.9% (difference 26.7%, 95% CI 20.6-32.8, p<0.001); FIL100 69.8% vs placebo 49.9% (difference 19.9%, 95% CI 13.6-26.2, p<0.001)
NCT02873936: ACR20 response at Week 12: filgotinib 200mg 66.0%, filgotinib 100mg 57.5%, placebo 31.1%; difference vs placebo 34.9% (95% CI 23.5-46.3) and 26.4% (95% CI 15.0-37.9) respectively, both P<.001
HLX01 (Hanlikang)Phase 3Monoclonal antibodyCD20Reliable signalNo reviewed efficacy summary in this indication
IguratimodPhase 3—NF-kBPartial signal
NCT00965757: ACR20 response at week 24: iguratimod plus methotrexate 69.5% vs placebo plus methotrexate 30.7% (P < 0.001), n=164 vs 88 (Ishiguro et al., Mod Rheumatol 2013).
Levilimab (Ilsira)Phase 3Monoclonal antibodyIL-6 receptorReliable signal
NCT04227366: ACR20 response at week 12: 68.6% (levilimab + methotrexate) vs 38.5% (placebo + methotrexate).
TelitaciceptPhase 3Protein / enzyme therapeuticBAFF / APRILnot yet gradedNo reviewed efficacy summary in this indication
ZemprocitinibPhase 3Small moleculeJAK1not yet gradedNo reviewed efficacy summary in this indication
AfimkibartPhase 2Monoclonal antibodyTL1Anot yet gradedNo reviewed efficacy summary in this indication
AZD1163Phase 2Biologic (subtype unspecified)PAD2 and PAD4 (peptidyl arginine deiminase 2/4)not yet gradedNo reviewed efficacy summary in this indication
BlinatumomabPhase 2Multispecific antibodyCD19 x CD3not yet gradedNo reviewed efficacy summary in this indication
CKD-506Phase 2Small moleculeHDAC6 (Histone deacetylase 6)Partial signal
NCT04204603: Primary endpoint, change from baseline in DAS28(CRP) at week 12 (full analysis set, n=121): placebo -1.2, CKD-506 200 mg -1.0, 400 mg -1.3, 600 mg -1.2; pre-specified dose-response trend test p > 0.5 (EudraCT 2018-001377-24 posted results). missed
Denosumab (Prolia)Phase 2Monoclonal antibodyRANKLPartial signal
NCT03239080: Erosion healing at 24 months: 20% (denosumab) vs 6% (placebo), p=0.045.
NCT00095498: Primary endpoint (change from baseline in MRI erosion score at 6 months): denosumab 60 mg +0.13 (P=0.118, not significant) vs denosumab 180 mg +0.06 (P=0.007, significant) vs placebo +1.75. Modified Sharp erosion score: 180 mg significant vs placebo at 6 months (P=0.019); both 60 mg (P=0.012) and 180 mg (P=0.007) significant vs placebo at 12 months.
ImeroprubartPhase 2Monoclonal antibodyFcRnnot yet gradedNo reviewed efficacy summary in this indication
JAB-8263Phase 2Small moleculeBET bromodomain proteins (e.g. BRD4)not yet gradedNo reviewed efficacy summary in this indication
LutikizumabPhase 2Multispecific antibodyIL-1α/IL-1β (dual)not yet gradedNo reviewed efficacy summary in this indication
MK-8690Phase 2Monoclonal antibodyCD30 ligand (CD30L / CD153)not yet gradedNo reviewed efficacy summary in this indication
NatrunixPhase 2Monoclonal antibodyIL-1 alphaPartial signalNo reviewed efficacy summary in this indication
RavagalimabPhase 2Monoclonal antibodyCD40not yet gradedNo reviewed efficacy summary in this indication
RosnilimabPhase 2Monoclonal antibodyPD-1 (agonist)not yet gradedNo reviewed efficacy summary in this indication
SHR-3045Phase 2UndisclosedPD-1not yet gradedNo reviewed efficacy summary in this indication
AZD0120Phase 1/2Cell therapyBCMA / CD19not yet gradedNo reviewed efficacy summary in this indication
ABBV-319Phase 1Antibody–drug conjugateCD19not yet gradedNo reviewed efficacy summary in this indication
ABBV-519Phase 1—CD19not yet gradedNo reviewed efficacy summary in this indication
AZD5492Phase 1Multispecific antibodyCD20 x CD3not yet gradedNo reviewed efficacy summary in this indication
AZD6912Phase 1RNA / oligonucleotideComplement Factor B (CFB) mRNAWeak signalNo reviewed efficacy summary in this indication
CLN-978Phase 1Multispecific antibodyCD19 x CD3not yet gradedNo reviewed efficacy summary in this indication
GSK5926371
Phase 1(overall)
Biologic (subtype unspecified)CD19 / CD20 (dual-antigen) with CD3 T-cell engagementnot yet gradedNo reviewed efficacy summary in this indication
SAR448501Phase 1Multispecific antibodyCD20not yet gradedNo reviewed efficacy summary in this indication
SurovatamigPhase 1Multispecific antibodyCD19 x CD3not yet gradedNo reviewed efficacy summary in this indication
UTAA91Phase 1Cell therapyCD19 (B cells) and PD-1+ pathogenic T cellsnot yet gradedNo reviewed efficacy summary in this indication
AB-101 (AlloNK)DiscontinuedCell therapyCell therapynot yet gradedNo reviewed efficacy summary in this indication

Large race: only the 66 furthest-along competitors are listed; 17 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(35 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Hydroxychloroquine to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (3)
December 2026 (3)
Phase 2Metastatic Colorectal CancerActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-24 · NCT05843188 · CT.gov ↗
What to watch
Phase 2Sudden Hearing LossRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-31 · NCT06467526 · CT.gov ↗
What to watch
Phase 2Primary Sjögren SyndromeEnrolling by invitationStudy of the molecule, not a specific product
Est. primary completion 2026-12-31 · NCT06519617 · CT.gov ↗
What to watch
2027 (11)
January 2027 (1)
Phase 2COVID-19RecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-01 · NCT05041907 · CT.gov ↗
What to watch
May 2027 (2)
Phase 1/2Prostate Cancer Recurrent, Solid Tumor, AdultRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-05-21 · NCT05036226 · CT.gov ↗
What to watch
Phase 1/2Recurrent Osteosarcoma, Refractory OsteosarcomaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-05-31 · NCT03598595 · CT.gov ↗
What to watch
June 2027 (1)
Phase 1/2Adenocarcinoma of the PancreasRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-06 · NCT04911816 · CT.gov ↗
What to watch
July 2027 (1)
Phase 2Breast CancerActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-07 · NCT04841148 · CT.gov ↗
What to watch
September 2027 (1)
Phase 2Parkinson&Amp;#39;s DiseaseActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-09 · NCT06816810 · CT.gov ↗
What to watch
November 2027 (1)
Phase 2Interstitial Lung DiseaseNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-11-01 · NCT07443436 · CT.gov ↗
What to watch
December 2027 (4)
Phase 2Breast CancerRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12 · NCT04523857 · CT.gov ↗
What to watch
Phase 2Pulmonary TuberculosisNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12 · NCT07467252 · CT.gov ↗
What to watch
Phase 2IgA NephropathyRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-31 · NCT06350630 · CT.gov ↗
What to watch
Phase 3PreeclampsiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-31 · NCT05287321 · CT.gov ↗
What to watch
2028 (10)
January 2028 (2)
Phase 2Rheumatic DiseaseRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-01 · NCT07138898 · CT.gov ↗
What to watch
Phase 2Advanced Biliary Tract Carcinoma, Advanced Colorectal Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma …RecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-01-04 · NCT05733000 · CT.gov ↗
What to watch
March 2028 (1)
Phase 3Rheumatoid ArthritisRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-03 · NCT03414502 · CT.gov ↗
What to watch
June 2028 (3)
Phase 1Acute Myeloid LeukemiaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-06 · NCT07814339 · CT.gov ↗
What to watch
Phase 3Respiratory Tract Diseases, Influenza (Pandemic), Influenza, Community Acquired Pneumonia, Community Acquired Pneumonia (CAP) …RecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-06 · NCT02735707 · CT.gov ↗
What to watch
Phase 2Ovarian CancerRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-06-18 · NCT06971744 · CT.gov ↗
What to watch
July 2028 (1)
Phase 2Arthritis, ArthralgiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-07 · NCT04354649 · CT.gov ↗
What to watch
September 2028 (1)
Phase 3PneumoniaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-09-30 · NCT04381936 · CT.gov ↗
What to watch
December 2028 (2)
Phase 3Systemic Lupus ErythematosusRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-12-31 · NCT05799378 · CT.gov ↗
What to watch
Early phase / not applicableSystemic Lupus ErythematosusNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-12-31 · NCT07675291 · CT.gov ↗
What to watch
2029 (6)
February 2029 (1)
Phase 1Resectable Localized Prostate CancerRecruitingStudy of the molecule, not a specific product
Est. primary completion 2029-02 · NCT06408298 · CT.gov ↗
What to watch
July 2029 (2)
Phase 3Hormone Receptor-Positive and HER2-Negative Advanced Breast CancerNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2029-07-01 · NCT07061717 · CT.gov ↗
What to watch
Phase 4Sarcoidosis, PulmonaryRecruitingStudy of the molecule, not a specific product
Est. primary completion 2029-07-01 · NCT05841758 · CT.gov ↗
What to watch
August 2029 (1)
Phase 4IgA Nephropathy, Renal Insufficiency, Chronic, IgA Vasculitis, IGA GlomerulonephritisRecruitingStudy of the molecule, not a specific product
Est. primary completion 2029-08 · NCT06676384 · CT.gov ↗
What to watch
September 2029 (1)
Phase 1/2Hepatocellular CarcinomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2029-09-30 · NCT05842174 · CT.gov ↗
What to watch
December 2029 (1)
Phase 2Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS), Joint Pain, Breast CancerRecruitingStudy of the molecule, not a specific product
Est. primary completion 2029-12 · NCT07825454 · CT.gov ↗
What to watch
2030 (3)
June 2030 (1)
Phase 4Psoriasis, Atopic DermatitisNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2030-06-01 · NCT07352566 · CT.gov ↗
What to watch
July 2030 (1)
Phase 2Melanoma Metastatic, NRAS MutationRecruitingStudy of the molecule, not a specific product
Est. primary completion 2030-07-28 · NCT07750067 · CT.gov ↗
What to watch
December 2030 (1)
Phase 3Steatohepatitis, NonalcoholicRecruitingStudy of the molecule, not a specific product
Est. primary completion 2030-12-31 · NCT07265297 · CT.gov ↗
What to watch
2034 (1)
December 2034 (1)
Phase 3Rheumatic Fever, Rheumatic Heart Disease in Children, Acute Rheumatic Fever, Rheumatic Heart DiseaseNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2034-12 · NCT07830108 · CT.gov ↗
What to watch
2035 (1)
March 2035 (1)
Early phase / not applicableRecurrent Pregnancy Loss, Euthyroid With Thyroid AntibodiesRecruitingStudy of the molecule, not a specific product
Est. primary completion 2035-03 · NCT06652113 · CT.gov ↗
What to watch

See the full readout calendar ↗